HC Wainwright Issues Pessimistic Forecast for Gossamer Bio (NASDAQ:GOSS) Stock Price

Gossamer Bio (NASDAQ:GOSS) had its price target cut by HC Wainwright from $10.00 to $5.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the stock. Leerink Partners downgraded shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. The Goldman Sachs Group downgraded shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Barclays downgraded shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Gossamer Bio presently has an average rating of “Hold” and a consensus target price of $5.43.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $0.50 on Friday. The company has a market cap of $115.89 million, a price-to-earnings ratio of -0.73 and a beta of 2.08. The stock’s 50-day moving average is $2.12 and its two-hundred day moving average is $2.58. Gossamer Bio has a 1-year low of $0.33 and a 1-year high of $3.87.

Institutional Trading of Gossamer Bio

Several institutional investors have recently modified their holdings of GOSS. Legal & General Group Plc acquired a new position in shares of Gossamer Bio in the 2nd quarter valued at $26,000. Ciovacco Capital Management LLC acquired a new position in Gossamer Bio in the third quarter valued at $27,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio in the second quarter valued at $27,000. MMA Asset Management LLC purchased a new position in shares of Gossamer Bio during the fourth quarter worth about $31,000. Finally, Soltis Investment Advisors LLC purchased a new position in shares of Gossamer Bio during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.